OncoSec Medical (OncoSec Medical) Days Sales Outstanding : 0.00 (As of Jan. 2023)

View and export this data going back to 1986. Start your Free Trial

What is OncoSec Medical Days Sales Outstanding?

OncoSec Medical's average Accounts Receivable for the three months ended in Jan. 2023 was $0.00 Mil. OncoSec Medical's Revenue for the three months ended in Jan. 2023 was $0.00 Mil.

The historical rank and industry rank for OncoSec Medical's Days Sales Outstanding or its related term are showing as below:

ONCSQ's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.665
* Ranked among companies with meaningful Days Sales Outstanding only.

OncoSec Medical's Days Sales Outstanding stayed the same from Jan. 2022 (0.00) to Jan. 2023 (0.00).

OncoSec Medical Days Sales Outstanding Historical Data

The historical data trend for OncoSec Medical's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Days Sales Outstanding Chart

OncoSec Medical Annual Data

Trend

Jul13

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Days Sales Outstanding

Get a 7-Day Free Trial

OncoSec Medical Quarterly Data
	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of OncoSec Medical's Days Sales Outstanding

For the Biotechnology subindustry, OncoSec Medical's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoSec Medical's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's Days Sales Outstanding falls into.

OncoSec Medical Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

OncoSec Medical's Days Sales Outstanding for the fiscal year that ended in Jul. 2022 is calculated as

	Days Sales Outstanding (A: Jul. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jul. 2021 )	+	Accounts Receivable (A: Jul. 2022 ))	/	count )	/	Revenue (A: Jul. 2022 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

OncoSec Medical's Days Sales Outstanding for the quarter that ended in Jan. 2023 is calculated as:

	Days Sales Outstanding (Q: Jan. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Oct. 2022 )	+	Accounts Receivable (A: Jan. 2023 ))	/	count )	/	Revenue (A: Jan. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

OncoSec Medical (OTCPK:ONCSQ) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

OncoSec Medical Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoSec Medical (OncoSec Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (OTCPK:ONCSQ) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

24 North Main Street, Pennington, NJ, USA, 08534

Website

https://www.oncosec.com

OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

Executives

Robert J Delaversano	officer: Principal Accounting Officer	217 W. MAIN STREET, SOMERVILLE NJ 08876
Spahr Stephany Foster	director	C/O ONCOSEC MEDICAL, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Robert H. Arch	officer: President and CEO	C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
George Chi	officer: Chief Financial Officer	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Lin Shi	director	24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218
Margaret Dalesandro	director	ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Yuhang Zhao	director	6 HORTON DR., CHESTER NJ 07930
Brian A Leuthner	officer: Chief Operating Officer	200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Daniel J. O'connor	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
China Grand Pharmaceutical & Healthcare Holdings Ltd	10 percent owner, other: See Remarks	UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000
Alpha Holdings, Inc.	director, 10 percent owner	GANGNAM-GU APGUJEONG-RO 62-GIL 17-10, SEOUL M5 06016
Kellie Malloy Foerter	officer: Chief Operating Officer	C/O ONCOSEC MEDICAL INCORPORATED, 24 N. MAIN STREET, PENNINGTON NJ 08534-2218
Herbert Kim Lyerly	director	C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218
Chao Zhou	director	UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000
Grand Decade Developments Ltd	10 percent owner, other: See Remarks	UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000